Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure
WARRINGTON, Pa., Sept. 28, 2022 -- Windtree Therapeutics, Inc. , a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported... | September 28, 2022
Source: marketscreener.com